Newly released report details Company’s achievements and plans for sustainable growth
Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy
Approval represents the first indication in the U.S. for TEVIMBRA
Newly Released Report Details Company’s Progress and Plans for Growing Responsibly
Announces commitment to become Founding Partner of The Prosperity ProjectTM